Factors influencing hesitancy towards adult and child COVID-19 vaccines in rural and urban West Africa: a cross-sectional study

Sylvain Landry B. Faye,1 Ralf Krumkamp,2,3 Seydou Doumbia,4,5 Moctar Tounkara,4,5 Ricardo Strauss,6 Henri Gautier Ouedraogo,6 Tani Sagna,6 Alpha Mahmoud Barry,7 Abdul Karim Mbawah,8 Cheick Oumar Doumbia,2,3,4,5 Souleymane Diouf,1 Kadari Cisse,6 Mohamed Harding,8 Paule Donven,2 Jürgen May,2,3 Dewi Ismajani Puradiredja,2 Daniela Fusco1,2,3

ABSTRACT

Objectives This study aims: (1) to identify and describe similarities and differences in both adult and child COVID-19 vaccine hesitancy; and (2) to examine sociodemographic, perception-related and behavioural factors influencing vaccine hesitancy across five West African countries.

Design Cross-sectional survey carried out between 5 May and 5 June 2021.

Participants and setting 4198 individuals from urban and rural settings in Burkina Faso, Guinea, Mali, Senegal and Sierra Leone participated in the survey.

Study registration The general protocol is registered on clinicaltrial.gov.

Results Findings show that in West Africa at the time only 53% of all study participants reported to be aware of COVID-19 vaccines, and television (60%, n=1345), radio (56%; n=1258), social media (34%; n=764) and family/friends/neighbours (28%; n=634) being the most important sources of information about COVID-19 vaccines. Adult COVID-19 vaccine acceptance ranges from 60% in Guinea and 50% in Sierra Leone to 11% in Senegal. This is largely congruent with acceptance levels of COVID-19 vaccinations for children. Multivariable regression analysis shows that perceived effectiveness and safety of COVID-19 vaccines increased the willingness to get vaccinated. However, sociodemographic factors, such as sex, rural/urban residence, educational attainment and household composition (living with children and/or elderly), and the other perception parameters were not associated with the willingness to get vaccinated in the multivariable regression model.

Conclusions Primary sources of information about COVID-19 vaccines include television, radio and social media. Communication strategies addressed at the adult population using mass and social media, which emphasise COVID-19 vaccine effectiveness and safety, could encourage greater acceptance also of COVID-19 child vaccinations in sub-Saharan countries.

Trial registration number NCT04912284.

INTRODUCTION

Sufficient immunisation coverage against COVID-19 in particular also in low-income and middle-income countries (LMICs) is crucial in addressing the current pandemic.1 In Africa, as elsewhere, reaching the necessary herd immunity threshold is jeopardised by factors, such as the emergence of new SARS-CoV2 variants, inequitable access to COVID-19 vaccines and vaccine hesitancy.2 Vaccine hesitancy can be defined as a ‘delay in acceptance or refusal of vaccination despite availability of vaccination services’ and can vary ‘across time, setting, and vaccines’.3,4 In Africa, a recent survey conducted among 15 countries indicates that acceptance of adult COVID-19 vaccines varies from 94% and 93%, respectively, in Ethiopia and Niger to 65% and 59%, respectively, in Senegal and the Democratic Republic of Congo.5–7 However, little is known about acceptance of child COVID-19 vaccines. Furthermore, there are concerns that without appropriate interventions even in settings with relatively high reported levels of willingness to get vaccinated compared with countries such as the USA and

To cite: Faye SLB, Krumkamp R, Doumbia S, et al. Factors influencing hesitancy towards adult and child COVID-19 vaccines in rural and urban West Africa: a cross-sectional study. BMJ Open 2022;12:e059138. doi:10.1136/bmjopen-2021-059138

Received 15 November 2021
Accepted 17 March 2022

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For correspondence and requests for reprints, email faye@bfim.org

For reprints or permission requests, please visit SAGE’s Rights and Permissions website at http://www.sagepub.com/journalsPermissions.nav

BMJ Open: first published as 10.1136/bmjopen-2021-059138 on 13 April 2022. Downloaded from http://bmjopen.bmj.com/ on September 16, 2023 by guest. Protected by copyright.
Russia, those who are still hesitant may shift to completely refusing or maintain passive avoidance in seeking out immunisation. High levels of COVID-19 vaccine hesitancy coupled with inequitable access to COVID-19 vaccines in LMICs represent a major problem in the global efforts to control the current COVID-19 pandemic. Furthermore, vaccine hesitancy might also revert the tremendous successes LMICs have made in increasing overall immunisation against other (childhood) infectious diseases if hesitancy towards COVID-19 vaccines translates into a more generalised hesitancy towards other vaccines, such as routine childhood vaccinations. Therefore, to build confidence and trust in COVID-19 vaccines, it is important to understand and address the reasons for vaccine hesitancy and the motivations behind the decision making of whether to get vaccinated or not. However, context-specific studies, which investigate factors influencing vaccine hesitancy towards adult and child COVID-19 vaccines in sub-Saharan Africa, are still far and few between. In this study, a community-based survey was carried out in five West African countries (Burkina Faso, Guinea, Mali, Senegal and Sierra Leone) in order to: (1) identify and describe similarities and differences in both adult and child COVID-19 vaccine hesitancy and (2) to examine sociodemographic, perception-related and behavioural factors influencing vaccine hesitancy across a subregion of Africa, which shares major cultural and geopolitical characteristics.

MATERIALS AND METHODS
Study area
The survey was conducted in the five West African countries Burkina Faso, Guinea, Mali, Senegal and Sierra Leone. In all study countries, study sites were selected in consultation with the local principal investigators from among urban and rural communities in and around the capital cities of the countries, namely Ouagadougou, Conakry, Bamako, Dakar and Freetown, respectively.

Sample size
The study size was calculated to estimate the proportion of the population willing to be vaccinated against COVID-19. Assuming a proportion of 0.5 (conservative estimate leading to the largest sampling size), 385 individuals had to be interviewed per study country to receive an estimate with 5% precision. These sample size considerations were met in all countries apart from Senegal, where a considerable proportion of respondents had to be excluded from the analysis as they had reported to have never heard of any COVID-19 vaccines.

Sampling strategy
Participants were selected from among the general population within predefined rural and urban study areas. Similar proportions of interviewees were selected from among rural and urban areas. The number of interviews to be conducted was based on the overall sample size and was proportionally allocated according to the population size within the sampling clusters. A random sample was drawn using an adjusted random walk procedure, a procedure used in previous immunisation coverage studies. Within each cluster between 8 and 12 random walks were conducted, and an equal number of interviews were conducted per random walk. Each random walk started on a randomly assigned location mark. For this purpose, geographical maps of the selected clusters were drawn, for which random coordinates were marked using ascending numbers. Valid sampling points (eg, coordinates pointing to a house or in the proximity of a house) on each map were identified by the field teams. Coordinates were selected in consecutive order from these valid location marks in order to start the random walks. The random walk procedure was applied to select study participants as described in Lemoshow and Robinson.

Once the sample was saturated per each starting point, a new one was used until the defined sample size was reached. Inclusion criteria for the study were: to be at least 18 years old, live in the study area and willingness to provide written informed consent. All those who did not meet the inclusion criteria were excluded from the study. In Senegal, the ethical commission asked to exclude from the study those who had been already vaccinated; for this reason, an additional exclusion criterion was added: have been offered the COVID-19 vaccination.

Data collection
Survey data were collected between 5 May and 5 June 2021. Respondents were invited to take part in face-to-face survey interviews using a 45-item questionnaire. The questionnaire uses measures as employed in other COVID-19 survey-based studies (eg, COSMO, COVID-19 Snapshot Monitoring, https://projekte.uni-erfurt.de/cosmo2020/web/) and were guided by the survey design recommendations by the WHO SAGE Working Group on Vaccine Hesitancy. Questions were discussed with all local PIs (Principal Investigators) and adapted as appropriate to the countries’ context. The questionnaires were completed by trained local fieldworkers on tablets with KoBoToolbox software (V.2.0) installed. Questionnaires were programmed to minimise data entry errors, for example, by applying predefined ranges for some variables. The questionnaire asked about respondents’ sociodemographic background characteristics and their perceptions, experience, confidence and decision making in relation to COVID-19 and COVID-19 vaccines, as well as past acceptance and perceptions of other vaccines. Depending on the preference of the respondents, interviews were conducted in French, English or one of the local languages. At the time of data collection, the COVID-19 vaccination roll-out was starting in the study countries, and part of our study population had already been offered a vaccine. In Senegal, this part of the population, on specific request of the country’s ethical commission, was excluded from the study analysis.
Analysis

The current study is a multicountry cross-sectional study. Descriptive statistics were used to apply plausibility checks, and no inconsistencies were found in the study data. Graphical and statistical methods were used to describe study data. Continuous variables were described using the median and the IQR, and categorical data were described using the frequency and percentages. Due to the exploratory nature of the study, no significance testing was applied. Some interviewees did not respond to all questions, and these missing data were excluded from the respective analysis. Thus, the denominator in some calculations may differ. Poisson regression models, with robust SEs, were calculated to analyse associations with vaccine hesitancy. For the model, vaccine hesitancy was dichotomised into no (definitely or probably do not want to be vaccinated) or yes (definitely or probably want to be vaccinated). Prevalence ratios (PRs) and the 95% CI were calculated. Categorical variables were dummy-coded to estimate PRs. This coding includes the categories yes, no and don’t know (dk). Bivariable models (outcome and one predictor variable) and multivariable regression model (outcome with all predictor variables, without variable selection) were calculated. Multivariable regressions were calculated for each country. Multilevel models to calculate pooled effect estimates were not applied because of the small number of countries. All analyses were done in R (V.4.1.0) using the sandwich packages (3.0–1) to calculate robust SEs.

Institutional review board and ethical considerations

Alongside a general study protocol, which defined the general rules for sampling strategy, sample size, selection of the recruitment areas and the ethical principles on which the survey is based on, country-specific protocols were developed. Data were collected according to a standard GCP procedure. The general protocol is registered on clinicaltrial.gov.

Patient and public

The patients and public were not involved in the design of the study and the research instrument mainly due to time constraints since the first survey wave was meant to be conducted in the early phases of vaccine rollout in the partner countries. However, the public has been engaged in the dissemination of the results. Two webinars (one in French and one in English) were organised on the 30 June 2021 in order to make the findings available to the local stakeholders in order to inform vaccination strategies in a timely manner. Additionally, individual reports have been submitted to the ethical commission of those countries, which have requested them so far (ie, Guinea and Mali).

RESULTS

Study population characteristics

Among the 4198 study participants, 2242 (53%) were aware of COVID-19 vaccines, and data of these individuals were used for subsequent analyses. Figure 1A shows vaccine awareness across the study countries. In Senegal, only 19% (n=149) of the interviewees had heard about vaccines against COVID-19; however, in the other countries, awareness ranged between 50% (n=428) in Sierra Leone and 70% (n=598) in Mali. Respondents' background characteristics stratified by country are described in table 1. In total, 1240 (55%) interviews were conducted in urban areas. The median age of the interviewees was 36 years with an IQR of 28–49 years and 42% (951) were female. The majority of study participants (1832; 85%) lived together with children and 39% (n=840) lived together with people aged ≥65 years. In total, 22% (n=496) had not completed any formal education, 19% (n=417) had attended primary/ middle school and 59% (1,329) secondary school or higher. At the time of the survey (May 2021), COVID-19 vaccination had already been offered to 480 (21%) of the interviewees, the majority of whom were in the Guinean study group (n=312; 56%). Half of the respondents who had already been offered a COVID-19 vaccination (n=240; 50%) had subsequently been vaccinated, again, with the largest number in the Guinean study group (n=181; 58%) (figure 1B). Study participants were asked about their main sources for information about COVID-19 vaccines (figure 2). Among all participants, the most important sources mentioned were television (60%, n=1345), radio (56%; n=1258), social media (34%; n=764) and family/friends/neighbours (28%; n=634). Governmental sources were only mentioned by 12% (n=262); however, 40% (n=172) of interviewees from Sierra Leone ranked this as an important information source.

Perceptions of COVID-19 and COVID-19 vaccines

Respondents’ perceptions of COVID-19 and COVID-19 vaccines are summarised in table 1. While more than half of all participants reported to be worried about the risk of
### Table 1  Respondent background characteristics (A) and their perceptions of COVID-19 and COVID-19 vaccines stratified by country (n=2242) (B)

|                    | Burkina Faso | Guinea | Mali | Senegal | Sierra Leone |
|--------------------|--------------|--------|------|---------|--------------|
|                    | n (%)        | n (%)  | n (%)| n (%)   | n (%)        |
| **A: background characteristics** |              |        |      |         |              |
| Total              | 506 (22)     | 561 (25)| 598 (27)| 149 (7) | 428 (19)     |
| Female gender      | 254 (50)     | 202 (36)| 226 (38)| 75 (50) | 194 (45)     |
| Age (years)*       | 34 (27–45)   | 34 (27–47)| 43 (18–54)| 35 (26–47) | 35 (27–45)   |
| Urban area         | 276 (55)     | 331 (59)| 366 (61)| 76 (51) | 191 (45)     |
| Vaccination offered| 9 (2)        | 312 (56)| 120 (20)| 0 (0)   | 39 (9)       |
| Vaccinated         | 1 (0)        | 181 (32)| 37 (6) | 0 (0)   | 23 (5)       |
| Living with children| 414 (88)    | 410 (77)| 556 (93)| 135 (92)| 317 (78)     |
| Living with elderly (≥65 years) | 79 (17)    | 188 (35)| 342 (57)| 94 (64) | 137 (34)     |
| Education          |              |        |      |         |              |
| No formal education| 113 (22)     | 121 (22)| 162 (27)| 31 (21) | 69 (16)      |
| Primary/middle school| 101 (20) | 96 (17) | 123 (21)| 57 (38) | 40 (9)       |
| Secondary school or higher| 292 (58) | 344 (61)| 313 (52)| 61 (41) | 319 (74)     |
| Ever refused a vaccination | 26 (5)    | 102 (18)| 69 (11) | 4 (3)   | 20 (5)       |
| ... for child      | 3 (12)       | 1 (1)  | 3 (5) | 2 (50) | 1 (7)        |
| ... for child/oneself| 2 (8)       | 10 (11)| 21 (34)| 0 (0)  | 2 (13)       |
| ... for oneself    | 21 (81)      | 84 (88)| 38 (61)| 2 (50) | 12 (80)      |
| **B: perceptions of COVID-19 and COVID-19 vaccines** |            |        |      |         |              |
| Worried about COVID-19 |            |        |      |         |              |
| No                 | 325 (65)     | 191 (35)| 171 (29)| 96 (64) | 136 (32)     |
| Yes                | 177 (35)     | 362 (65)| 421 (71)| 53 (36) | 290 (68)     |
| Feel at risk of infection |            |        |      |         |              |
| No                 | 253 (50)     | 187 (34)| 174 (29)| 80 (54) | 121 (28)     |
| Yes                | 179 (35)     | 244 (44)| 332 (56)| 36 (24) | 260 (61)     |
| Don’t know         | 73 (14)      | 126 (23)| 91 (15) | 33 (22) | 45 (11)      |
| Vaccine protects against COVID-19 |            |        |      |         |              |
| No                 | 81 (16)      | 17 (3) | 74 (13)| 40 (27) | 23 (5)       |
| Yes                | 329 (66)     | 434 (78)| 382 (66)| 87 (58) | 293 (69)     |
| Don’t know         | 91 (18)      | 107 (19)| 123 (21)| 22 (15) | 106 (25)     |
| COVID-19 vaccines are safe |            |        |      |         |              |
| No                 | 166 (33)     | 44 (8) | 152 (26)| 61 (41) | 19 (4)       |
| Yes                | 104 (21)     | 201 (37)| 129 (22)| 33 (22) | 175 (41)     |
| Don’t know         | 234 (46)     | 294 (55)| 304 (52)| 55 (37) | 230 (54)     |
| Concerned about side effects |            |        |      |         |              |
| No                 | 63 (13)      | 130 (24)| 129 (22)| 22 (15) | 24 (6)       |
| Yes                | 395 (79)     | 327 (60)| 321 (55)| 120 (81)| 266 (63)     |
| Don’t know         | 42 (8)       | 90 (16) | 134 (23)| 7 (5)   | 134 (32)     |
| COVID-19 vaccines carry more risks |            |        |      |         |              |
| No                 | 57 (12)      | 144 (26)| 77 (13)| 20 (13) | 26 (6)       |
| Yes                | 307 (62)     | 156 (28)| 283 (49)| 104 (70)| 167 (39)     |
| Don’t know         | 130 (26)     | 249 (45)| 221 (38)| 25 (17) | 231 (54)     |

*Median age and IQR (in brackets).
getting infected with SARS-CoV-2 (n=1303, 59%), there were variations between countries ranging from 71% (n=421) of respondents who reported to be concerned about getting infected in Mali to only 35% (n=177) and 36% (n=53), in Burkina Faso and Senegal, respectively. Almost half of the interviewees felt currently at risk of getting infected (n=1051; 47%) with Sierra Leone having the highest number of respondents who reported to feel currently at risk of getting infected (n=260; 61%). While 69% (n=1525) of the study participants believe that the vaccine protects against COVID-19, half of the interviewed individuals reported to be unsure whether the vaccine is safe. In fact, in Senegal, 41% of the respondents (n=61) said that they believe COVID-19 vaccines to be unsafe. A considerable proportion of all respondents (n=1429; 65%) voiced concern about vaccine side effects, with the highest levels of concern reported in Senegal (n=120; 81%) and Burkina Faso (n=395, 79%). About half of the participants (n=1017; 46%) think COVID-19 vaccines carry more risk than routine vaccines. This perception varies from 62% in Burkina Faso (n=307) who believe this to be the case to 28% in Guinea (n=156).

Vaccine acceptance, hesitancy and refusal in five West Africa countries

Overall, 39% (n=865) of the study population said they would definitely and 23% (n=514) would probably accept to get vaccinated against COVID-19, while 21% (n=465) of all participants would definitely and 13% (n=287) would probably refuse vaccination. COVID-19 vaccine acceptance ranged from 60% (n=330) in Guinea to 11% (n=16) in Senegal, whereas vaccine hesitancy ranged from 41% (n=58) in Senegal to 10% (n=58) in Guinea (figure 3A). Similarly, when asked about their willingness to have their own children vaccinated against COVID-19 in case a vaccine would be licenced for that age group, 36% (n=705) responded that they would accept, 25% (n=532) that they would refuse, whereas the remainder reported either that they would probably vaccinate their children against COVID-19 (21%; n=448), or that they would probably not have their children vaccinated (11%; n=235). Again, COVID-19 vaccine acceptance for children was highest in Guinea (n=283; 53%) and Sierra Leone (n=179; 47%) and the lowest in Senegal (n=9; 7%) (figure 3B). Figure 3C shows the congruence of those who would accept, hesitate or refuse vaccination against COVID-19 for themselves, with those who would do so when it comes to their own children. Eighty per cent (n=1690) of the respondents show the same level of willingness in both cases.

Factors influencing acceptance, hesitancy and refusal

Of all respondents 1926 (86%) who were included in the Poisson regression models (figure 4), 29% came from Burkina Faso (n=433), 25% from Guinea (n=484), 27% from Mali (n=524), 7% (n=132) from Senegal and 18% (n=353) from Sierra Leone. Study participants with missing values in the independent variables had to be excluded from the regression analysis.

Results from the bivariable (figure 4A) and multivariable (figure 4B) regression are summarised in figure 4. The multivariable regression (figure 4B) showed that the perceived effectiveness of a vaccine to protect from COVID-19 and safety of COVID-19 vaccines increased the willingness to get vaccinated. Strongest associations with the perception of vaccine protection were observed for Burkina Faso (PR=6.1; 95% CI 2.6 to 14.4), Sierra Leone (PR=4.3; 95% CI 1.5 to 12.2) and Senegal (PR=4.2; 95% CI 1.0 to 18.0). Strongest association with vaccine safety was shown for Senegal (PR=6.5; 95% CI 2.4 to 17.9), while for the other countries PRs about two or lower were observed. However, sociodemographic factors, such as sex, rural/urban residence, educational attainment and household composition (living with children and/or elderly), and the other perception parameters were not associated with the willingness to get vaccinated in the multivariable regression model. In the bivariable regression analysis (figure 4A), the belief that the vaccine has side effects or that the vaccine carries more risks compared with routine vaccines lowers the willingness to...
get vaccinated. However, this effect was no longer present in the multivariable regression, which could indicate that associations were confounded. Overall, the findings were fairly consistent across countries.

**DISCUSSION**
This study presents findings from a multicountry survey on a thus far under-researched topic: factors influencing COVID-19 adult and child vaccine hesitancy in sub-Saharan Africa. Main findings from the survey, which was conducted in five West African countries (Burkina Faso, Guinea, Mali, Senegal and Sierra Leone) include, first, that at the time of data collection overall levels of COVID-19 vaccine awareness were strikingly low. Out of the 53% of respondents (n=2242) who reported to be aware of COVID-19 vaccines, levels of COVID-19 vaccine acceptance varied and ranged from 60% (n=330) in Guinea to 11% (n=16) in Senegal, conversely vaccine hesitancy ranged from 41% (n=58) in Senegal to 10% (n=58) in Guinea (figure 3A). One explanation for the lower levels of vaccine hesitancy in Guinea and Sierra Leone could be that these two countries have built on experiences from past epidemics, such as the devastating Ebola epidemic in 2014–2016 and greater exposure to Ebola vaccinations and vaccination campaigns. It is possible that the major investments in community-based interventions to increase the acceptability of a newly released vaccine might have a role in the greater acceptance of vaccines against COVID-19.

Second, to our knowledge, this study is the first to look into the relationship between acceptance of both adult and child COVID-19 vaccinations in sub-Saharan Africa. Our findings show that the adults’ willingness to get vaccinated was largely congruent with the intention to have their own children...
vaccinated against COVID-19 should an appropriate vaccine becomes available/accessible (figure 3C). This stands in contrast to previous research, for instance in England, which shows that study participants were more likely to accept a COVID-19 vaccine for themselves than their child/children.\textsuperscript{20} However, other studies in high-income countries have shown that adult vaccine hesitancy may further reduce parental intent to have their children vaccinated, through mechanisms such as distrust, and concerns around vaccine safety and efficacy.\textsuperscript{21} This may suggest that as COVID-19 vaccination strategies are moving towards child immunisation\textsuperscript{22} in our study region, communication and awareness-raising approaches targeting adults may also have a positive impact on COVID-19 vaccine coverage of children.

Third, consistent with other studies, vaccine hesitancy among the study countries is primarily explained by concerns over the safety and effectiveness of COVID-19 vaccines,\textsuperscript{23–25} rather than age or educational attainment.\textsuperscript{8} However, in contrast to other studies on vaccine hesitancy in LMIC, gender and rural versus urban setting did not explain the difference.\textsuperscript{26}

Furthermore, it is noteworthy that the most popular source of COVID-19 related information among the study population are television, radio and social media, rather than, for example, governmental sources and healthcare workers (figure 2), which is in line with recent literature.\textsuperscript{27} Previous research has shown that individuals who inform themselves mostly relying on social media as primary source of information are more likely to be hesitant than those drawing more on professional sources of information.\textsuperscript{28} Thus, as shown by research concerned with other health topics, such as reproductive health, HIV and other sexually transmitted infections, social media needs to be used more effectively as a tool to communicate correct and appropriate information about COVID-19 vaccinations.\textsuperscript{29,30}

Overall, only 39\% of all participants included in the study reported that they would accept a vaccination against COVID-19, 21\% in the group said they would refuse and 36\% said they were still hesitant. Strikingly, 55\% of those who had previously been offered vaccination against COVID-19 declined it when the opportunity arose (figure 1B). Considerable levels of COVID-19 vaccine hesitancy and refusal coupled with inequitable access to vaccines and suboptimal vaccination coverage represent a complex challenge in these countries. Going forward, the possibility of a detrimental knock-on effect of lack of confidence in COVID-19 vaccines on the uptake of, for instance, childhood routine vaccinations, should be considered. There is evidence to suggest that this could revert the tremendous successes African countries have had in terms of increasing access to immunisation and reducing child deaths.\textsuperscript{31}

Finally, while this study managed to conduct a baseline survey in a timely manner to capture the moment in time when COVID-19 vaccination campaigns—for both adults and children—had not yet or only just started to roll out in a region of Africa that has a number of common historical, cultural and geopolitical characteristics, it is not without limitations. First, the study relied on self-reported perceptions and behaviour, and responses are therefore susceptible to social desirability bias. However, trained local fieldworkers experienced in administering survey questionnaires and fluent in local languages and dialects helped to minimise this risk. Furthermore, the survey included both urban and rural areas; however, the rural areas surrounding the capital cities may not be representative of more remote settings. The estimated target sample sizes were met in four out of the five study countries. However, in Senegal, there were particular ethical requirements that needed to be adhered to, and there was a particularly high number of respondents who reported to not be aware of COVID-19 vaccines, which led to a limited number of observations and decreased the power of the data collected for this country. Finally, data are drawn from a cross-sectional survey, meaning that conclusions cannot be made regarding causality of relationships. Going forward, longitudinal research is needed to monitor vaccine hesitancy and its determinants in this region over time.

CONCLUSION

High vaccination coverage represents one of the most effective measures to mitigate the impact of the COVID-19 pandemic\textsuperscript{32} but is jeopardised by vaccine hesitancy. Addressing vaccine hesitancy is particularly relevant in countries, where access to vaccines is limited. Communication strategies addressed at the adult population using mass and social media and emphasising vaccine efficacy and safety could encourage greater acceptance also towards COVID-19 childhood vaccinations in the countries included in the study.

Author affiliations

1Department of Sociology, Université Cheikh Anta Diop Faculté des Lettres et Sciences Humaines, Dakar, Senegal
2Department of Infectious Disease Epidemiology, Bernhard Nocht Institute of Tropical Medicine, Hamburg, Germany
3German Center for Infection Research (DZIF), Hamburg-Borstel-Lübeck-Riems, Germany, Hamburg, Germany
4Département d’Enseignement et de Recherche en Santé Publique et Spécialités, Faculté de Médecine et d’Odontostomatologie-Université des Sciences, des Techniques et des Technologies, USTTB, Bamako, Mali
5University Clinical Research Center (UCRC), Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali
6Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique, Ouagadougou, Burkina Faso, Ouagadougou, Centre, Burkina Faso
7Gamal Abdel Nasser University of Conakry, Santé Pus Organization, Conakry, Guinea
8University of Sierra Leone, College of Medical – Medicine and Allied Health Sciences (COMAHS), Freetown, Western Area, Sierra Leone

Acknowledgements We are grateful to all the participants and the field team including drivers and IT staff who contributed to the success of the study. A special mention to data collectors: Burkina Faso: Mamadou Baduon, Adiaratou Bamba, Betiani Pierre Coulibaly, Mohamed Darbe, Ingrid Keré, Oumpanhala Elisée Lombo, Aboubacar B Ouattara, Charles Henri Ouedraogo, Wendetou Alhadi Ouedraogo, Paterno Wendopoure Sawadogo, Ramonède-Wendé Alphonson Irène Sawadogo, Wendogouda Félicité Taposba, Rokia Yabré, Moustapha Yoa; Guinea: Fatoumata Addama Diallo, Roafoudaï Said, Ahmed Dhoukouré, Barry Abdoussahmane Barry, Tolona Macky Tolno, Mamadou Lamaranah Día Diallo, Mamadou Maladho Diallo, Mariam Camara, Ansoumame Sangare, Maryloutou Diallo, Thierno Mamadou Diallo, Fode Youssouf Diallo, Mamadou Oury Diallo, Fatoumata Binta Bah, Pascal Traore, Soufyaneh Mohamad Ahmed, Fatoumata Binta Kann, Adama Sangare, Hassane

Faye SLB, et al. BMJ Open 2022;12:e059138. doi:10.1136/bmjopen-2021-059138
REFERENCES

1 Viana J, van Dorp CH, Nunes A, et al. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun 2021;12:1–15.
2 Aschwanden C. Five reasons why COVID herd immunity is probably impossible. Nature 2021;591:520–2.
3 Lazarus JV, Ratzan SC, Palayew A. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID-19. Vaccines 2021;9:19–21.
4 MacDonald NE, Eskola J, Liang X, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine 2015;33:4161–4.
5 Tomerio-Molina J, Sánchez-Alonso F, Fernández-Pradaa M. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID-. Ann Oncol 2020;20:19–22.
6 Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021;27:225–8.
7 AFRICA CDC. COVID-19 Vaccine Perceptions: A 15-country study [Internet]. 2021. Available: file:///Users/danielasfascu/Downloads/COVID-19%20Vaccine%20Perception%20Survey%20Final%20Report%202021.02.21%20v1.01.pdf.
8 Solis Arce JS, Warren SS, Meriggi NF, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med 2021;27:1385–94.
9 Elkebeldem OC, Yuna I, Onyeaka H, et al. COVID-19 vaccine rollout: will it affect the rates of vaccine hesitancy in Africa? Public Health 2021;197:12–14.
10 Truong J, Bakshi S, Waisim A. What factors promote vaccine hesitancy or acceptance during pandemics? A systematic review and thematic analysis. Health Promot Int 2021;36:dbab105.
11 Bangura JB, Xiao S, Qiu D, et al. Barriers to childhood immunization in sub-Saharan Africa: a systematic review. BMC Public Health 2020;20:1108.
12 Defor S, Kwame A, Agyegpong IA. Understanding the state of health policy and systems research in West Africa and capacity strengthening needs: Scoping of peer-reviewed publications and trends 1990–2015. Health Res Policy Syst 2017;15:55.
13 Uneke CJ, Sombie I, Johnson E, et al. Lessons learned from strategies for promotion of evidence-to-policy process in health interventions in the ECOWAS region: a rapid review. Niger Med J 2020;61:227.
14 WHO. Vaccination coverage cluster surveys: reference manual. 2015; 3.
15 Lemeshev S, Robinson D. Surveys to measure programme coverage and impact: a review of the methodology used by the expanded programme on immunization. World Health Stat Q 1983;38:65–75.
16 Larson HJ, Jarrett C, Schulz WS, et al. Measuring vaccine hesitancy: the development of a survey tool. Vaccine 2015;33:4165–75.
17 Ahanhanzo CO, Johnson EAK, Eboreime EA, et al. COVID-19 in West Africa: regional resource mobilisation and allocation in the first year of the pandemic. BMJ Glob Health 2021;6:e004762–11.
18 Kucharski AJ, Eggo RM, Watson CH, et al. Effectiveness of ring vaccination as control strategy for Ebola virus disease. Emerg Infect Dis 2016;22:105–8.
19 Lhomme E, Modet C, Augier A, et al. Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context. Trans R Soc Trop Med Hyg 2019;103:1–6.
20 Bell S, Clarke R, Mounier-Jack S, et al. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine 2020;38:7789–98.
21 Temsah M-H, Alhuzaimi AN, Aljaamaa F, et al. Parental attitudes and hesitancy about COVID-19 vs. routine childhood vaccinations: a national survey. Front Public Health 2021;9:752323.
22 Ledford H. Should children get COVID vaccines? what the science says. Nature 2021;595:638–9.
23 Kaplan RM, Mlislein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci U S A 2021;118:2021276118.
24 Malik AA, McFadden SM, Eboreime JA, et al. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine 2020;26:100495.
25 Kreps S, Dasgupta N, Brownstein JS, et al. Public attitudes toward COVID-19 vaccination: the role of vaccine attributes, incentives, and misinformation. npj Vaccines 2021;6:1–7.
26 Bono SA, Faria de Moura Villela E, Siau CS, et al. Factors affecting COVID-19 vaccine acceptance: an international survey among low- and middle-income countries. Vaccines 2021;9:515.
27 Gilk D, Massey P, Gipsen J, et al. Health-Related media use among youth audiences in Senegal. Health Promot Int 2016;31:73–82.
28 Du F, Chantler T, Francis MR, et al. Access to vaccination information and confidence/hesitancy towards childhood vaccination: a cross-country survey in China. Vaccines 2021;9:201–13.
29 Borzekowski DLG, Fobil JN, Asante KO. Related media use among young audiences in Senegal. Health Promot Int 2016;31:73–82.
30 Du F, Chantler T, Francis MR, et al. Access to vaccination information and confidence/hesitancy towards childhood vaccination: a cross-country survey in China. Vaccines 2021;9:201–13.
31 Denno DM, Hoopes AJ, Chandra-Mouli V. Effective strategies to provide adolescent sexual and reproductive health services and to increase demand and community support. J Adolesc Health 2015;56:S22–41.
32 Adamu AA, Jalo RI, Habonimana D. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID-19. J Adolesc Health 2015;56:S22–41.
33 Marziano V, Guzzetta G, Mamnone A. Return to normal: COVID-19 vaccination under mitigation measures. medRxiv 2021:2021.03.19.21253893.